MedTrace Logo

Hybrid Closed-Loop Insulin Delivery System in Type 1 Diabetes Candidates for a Living Donor Kidney Transplant

NCT03494010 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-03-09

No results posted yet for this study

Summary

The investigators' primary aim is to determine the impact of using hybrid closed-loop (HCL) system in patients with type 1 diabetes (T1D) and end stage renal disease (ESRD) prior to kidney transplantation.

The investigators will also determine whether HCL, by improving glucose control, will affect short-term (1 month) and long-term (12 months) complications after kidney transplantation in patients with T1D.

Conditions

  • Diabetes, Type 1

Interventions

OTHER

Observation

There is no intervention. Patients will receive the HCL system as part of their clinical care.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Renata Belfort De Aguiar, MD, PhD · Yale University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-31
Primary Completion
2020-04-30
Completion
2021-04-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03494010 on ClinicalTrials.gov